NALIRIFOX
Sponsors
Memorial Sloan Kettering Cancer Center, UNC Lineberger Comprehensive Cancer Center, University of Kansas Medical Center, Taichung Veterans General Hospital, Affiliated Cancer Hospital of Shantou University Medical College
Conditions
Basal Cell NeoplasmColorectal Cancer (CRC)Metastatic Pancreatic CancerNENSPancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)
Phase 1
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
RecruitingNCT06483555
Start: 2025-02-06End: 2027-08-01Target: 104Updated: 2026-04-23
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
RecruitingNCT06736717
Start: 2025-02-28End: 2027-01-31Target: 21Updated: 2025-02-06
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
RecruitingNCT07030283
Start: 2025-12-31End: 2030-07-01Target: 10Updated: 2026-02-02
Phase 2
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingNCT05851924
Start: 2023-05-12End: 2027-05-01Target: 60Updated: 2026-06-08
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
RecruitingNCT06816914
Start: 2025-03-05End: 2028-02-05Target: 84Updated: 2025-02-20
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
RecruitingNCT07077551
Start: 2025-04-22End: 2028-12-31Target: 28Updated: 2025-07-22
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingNCT07163273
Start: 2025-06-20End: 2027-06-20Target: 41Updated: 2026-03-18